Multivitamin supplements may affect warfarin anticoagulation in susceptible patients

被引:21
作者
Kurnik, D
Lubetsky, A
Loebstein, R
Almog, S
Halkin, H [1 ]
机构
[1] Chaim Sheba Med Ctr, Div Clin Pharmacol & Toxicol, IL-52621 Tel Hashomer, Ramat Gan, Israel
[2] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
[3] Chaim Sheba Med Ctr, Dept Hematol, Inst Thrombosis & Hemostasis, IL-52621 Tel Hashomer, Israel
[4] Chaim Sheba Med Ctr, Inst Clin Pharmacol & Toxicol, Tel Hashomer, Israel
关键词
multivitamins; warfarin; antagonists and inhibitors;
D O I
10.1345/aph.1D102
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report an interaction of a multivitamin preparation containing small amounts of vitamin K-1 (25 mug) with warfarin in a case series and to assess the prevalence of vitamin K, deficiency in ambulatory anticoagulated patients. CASE SUMMARIES: We describe 3 patients whose anticoagulation was stabilized with warfarin in whom initiation or cessation of a self-prescribed multivitamin supplement delivering 25 mug of vitamin K-1 daily was associated with an otherwise unexplained significant fall or rise in international normalized ratio (INR), respectively, with major thrombosis or hemorrhage in 2. This interaction was rated probable on the Naranjo probability scale. Suspecting vitamin K, deficiency as an explanation for this oversensitivity, we assessed the prevalence of vitamin K-1 deficiency in our clinic by determining plasma vitamin K-1 levels in 179 stable consecutive patients, finding very low levels (<0.1 ng/mL) in 22 of 179 (12%). DISCUSSION: Vitamin K-1 supplements of 25 mug daily are far below the dose thought to affect anticoagulant control. We hypothesize that, in our patients, unsuspected vitamin K-1 deficiency caused an oversensitivity to small vitamin K-1 supplements. In patients with low vitamin K-1 status, even such low doses represent a significant increment in daily intake, thus lowering the sensitivity to warfarin. Our analysis suggests that low vitamin K-1 status exists in a small, but important, minority of ambulatory patients undergoing anticoagulation. CONCLUSIONS: Clinicians should instruct anticoagulated patients to report the use of multivitamin supplements and inquire about it in Gases of unexplained INR changes.
引用
收藏
页码:1603 / 1606
页数:4
相关论文
共 14 条
[1]   Patient-specific factors predictive of warfarin dosage requirements [J].
Absher, RK ;
Moore, ME ;
Parker, MH .
ANNALS OF PHARMACOTHERAPY, 2002, 36 (10) :1512-1517
[2]   Vitamin and mineral supplement use in the United States -: Results from the third national health and nutrition examination survey [J].
Balluz, LS ;
Kieszak, SM ;
Philen, RM ;
Mulinare, J .
ARCHIVES OF FAMILY MEDICINE, 2000, 9 (03) :258-262
[3]   The association of vitamin K status with warfarin sensitivity at the onset of treatment [J].
Cushman, M ;
Booth, SL ;
Possidente, CJ ;
Davidson, KW ;
Sadowski, JA ;
Bovill, EG .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (03) :572-577
[4]   INTERACTION OF DIETARY FACTORS WITH ORAL ANTICOAGULANTS - REVIEW AND APPLICATIONS [J].
HARRIS, JE .
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 1995, 95 (05) :580-584
[5]   Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range [J].
Hirsh, J ;
Dalen, JE ;
Anderson, DR ;
Poller, L ;
Bussey, H ;
Ansell, J ;
Deykin, D .
CHEST, 2001, 119 (01) :8S-21S
[6]  
Kamali F, 2000, THROMB HAEMOSTASIS, V84, P39
[7]  
KARLSON B, 1986, ACTA MED SCAND, V220, P347
[8]   Vitamin K intake and sensitivity to warfarin in patients consuming regular diets [J].
Lubetsky, A ;
Dekel-Stern, E ;
Chetrit, A ;
Lubin, F ;
Halkin, H .
THROMBOSIS AND HAEMOSTASIS, 1999, 81 (03) :396-399
[9]   Dietary and nondietary determinants of vitamin K biochemical measures in men and women [J].
McKeown, NM ;
Jacques, PF ;
Gundberg, CM ;
Peterson, JW ;
Tucker, KL ;
Kiel, DP ;
Wilson, PWF ;
Booth, SL .
JOURNAL OF NUTRITION, 2002, 132 (06) :1329-1334
[10]   A METHOD FOR ESTIMATING THE PROBABILITY OF ADVERSE DRUG-REACTIONS [J].
NARANJO, CA ;
BUSTO, U ;
SELLERS, EM ;
SANDOR, P ;
RUIZ, I ;
ROBERTS, EA ;
JANECEK, E ;
DOMECQ, C ;
GREENBLATT, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (02) :239-245